HomeCompareMKKGY vs KMB

MKKGY vs KMB: Dividend Comparison 2026

MKKGY yields 2.01% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MKKGY wins by $40.7K in total portfolio value· pulled ahead in Year 7
10 years
MKKGY
MKKGY
● Live price
2.01%
Share price
$24.90
Annual div
$0.50
5Y div CAGR
46.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$86.6K
Annual income
$27,878.31
Full MKKGY calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.47
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,211.33
Full KMB calculator →

Portfolio growth — MKKGY vs KMB

📍 MKKGY pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMKKGYKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MKKGY + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MKKGY pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MKKGY
Annual income on $10K today (after 15% tax)
$170.81/yr
After 10yr DRIP, annual income (after tax)
$23,696.56/yr
KMB
Annual income on $10K today (after 15% tax)
$445.84/yr
After 10yr DRIP, annual income (after tax)
$4,429.63/yr
At 15% tax rate, MKKGY beats the other by $19,266.93/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MKKGY + KMB for your $10,000?

MKKGY: 50%KMB: 50%
100% KMB50/50100% MKKGY
Portfolio after 10yr
$66.2K
Annual income
$16,544.81/yr
Blended yield
24.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

MKKGY
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
2.6
Piotroski
7/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.5% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MKKGY buys
0
KMB buys
0
No recent congressional trades found for MKKGY or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMKKGYKMB
Forward yield2.01%5.25%
Annual dividend / share$0.50$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR46.8%17%
Portfolio after 10y$86.6K$45.9K
Annual income after 10y$27,878.31$5,211.33
Total dividends collected$60.8K$21.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold

Year-by-year: MKKGY vs KMB ($10,000, DRIP)

YearMKKGY PortfolioMKKGY Income/yrKMB PortfolioKMB Income/yrGap
1$10,995$294.99$11,314$613.68$319.00KMB
2$12,210$444.99$12,865$759.19$655.00KMB
3$13,742$677.95$14,709$943.96$967.00KMB
4$15,751$1,046.87$16,919$1,180.17$1.2KKMB
5$18,500$1,646.22$19,588$1,484.33$1.1KKMB
6$22,448$2,652.71$22,838$1,879.06$390.00KMB
7← crossover$28,435$4,416.03$26,832$2,395.60+$1.6KMKKGY
8$38,100$7,674.63$31,788$3,077.63+$6.3KMKKGY
9$54,875$14,108.24$38,000$3,986.82+$16.9KMKKGY
10$86,595$27,878.31$45,872$5,211.33+$40.7KMKKGY

MKKGY vs KMB: Complete Analysis 2026

MKKGYStock

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment also provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. The Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.

Full MKKGY Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this MKKGY vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MKKGY vs SCHDMKKGY vs JEPIMKKGY vs OMKKGY vs KOMKKGY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.